论文部分内容阅读
LY295427(4-allylcholestan-3-ol)代表一种新型降脂药,它通过固醇调控因子结合蛋白(SREBP)作用于低密度脂蛋白受体(LDLR),进而增大血浆低密度脂蛋白LDL的清除率,以便达到降低胆固醇的作用效果。 LY295427能使受抑制的氧化固醇(oxysterol)介导的固醇调控因子结合蛋白的活化过程出现逆转,使活化转变而成活性,从而激活其调控LDLR基因。由于LDLR被活化,使LDL的代谢增加从而提高了血浆中LDL的清除率。 LY295427对氧化固醇的作用在于它能够增加氧
LY295427 (4-allylcholestan-3-ol) represents a new lipid-lowering drug that acts on low density lipoprotein receptor (LDLR) via the steroid regulatory factor binding protein (SREBP), thereby increasing the plasma level of low-density lipoprotein LDL The clearance rate, in order to achieve the effect of lowering cholesterol. LY295427 reverses the activation of the suppressed oxysterol-mediated sterol regulatory factor-binding protein and activates its activation to activate its regulation of the LDLR gene. As LDLR is activated, the metabolism of LDL is increased to increase the clearance of LDL in plasma. The effect of LY295427 on oxysterols is that it increases oxygen